Prognostic Value of Trop‐2 Expression in Nonmetastatic Triple‐Negative Breast Cancer and Correlation With Emerging Biomarkers
As Trop-2 expression appears nearly constant and independent of classical TNBC variables and outcome, association of anti-Trop-2 therapies with other targeted therapies can be evaluated without reducing the population in specific TNBC subgroups.
Authors
- Charles Theillet (ORCID: https://orcid.org/0000-0001-5555-2759)
- Florence Boissière‐Michot (ORCID: https://orcid.org/0000-0003-2431-5157)
- Virginie Lafont (ORCID: https://orcid.org/0000-0001-9612-3934)
- Séverine Guiu (ORCID: https://orcid.org/0000-0002-4901-6295)
- Nelly Firmin (ORCID: https://orcid.org/0000-0001-5839-6261)
- Marie‐Christine Chateau
- Gwendal Lazennec (ORCID: https://orcid.org/0000-0002-8522-1763)
- William Jacot (ORCID: https://orcid.org/0000-0001-7834-061X)
- Simon Thézenas (ORCID: https://orcid.org/0000-0003-2472-1219)
Institutions
- Centre National de la Recherche Scientifique (FR)
- Université de Montpellier (FR)
- Institut de Recherche en Cancérologie de Montpellier (FR)
- Modélisation et Ingénierie des Systèmes Complexes Biologiques pour le Diagnostic (FR)
- Alcen (France) (FR)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1002/cam4.70615
- Citations
- 3
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.81
Funders
- Daiichi Sankyo Europe